ACGIH: TWA 50 ppmOSHA: TWA 25 ppm; STEL 125 ppmNIOSH: IDLH 2300 ppm
介电常数：
9.1（22℃）
物理描述：
Thionyl chloride appears as a colorless to yellow fuming liquid with a suffocating pungent odor. Boiling point 79°C. A lachrymator. Highly corrosive and toxic. Long-term inhalation of low concentrations or short-term inhalation of high concentrations has adverse health effects.
Thionyl chloride is rapidly hydrolyzed to sulfur dioxide and hydrogen chloride and the metabolism and disposition follow those two compounds. Following inhalation, sulfur dioxide is distributed throughout the body after dissolving into surface fluid. Some remains in the respiratory system for a week or more following exposure. Urinary excretion clears it from the body. Hydrogen chloride dissolves in the nasal passages. Hydrogen chloride is not metabolized; however, hydrogen and chloride ions resulting from adsorption in the respiratory tract may be distributed throughout the body.
In view of its reactivity with water, moisture, etc., rapid hydrolysis upon contact with mucous membranes (eyes, respiratory tract) releaseing sulfur dioxide and hydrogen chloride can be expected.
IDENTIFICATION AND USE: Thionyl chloride is a colorless to pale yellow or reddish liquid. Thionyl chloride is an industrially produced liquid used to make acyl chlorides and to synthesize pharmaceuticals including drugs and vitamins. It is used to make dyes, to prepare organic chlorine compounds, as a solvent in the production of herbicides, and as an electrolyte in lithium batteries. Thionyl chloride is also used to prepare polyacrylate-type engineering thermoplastics made from iso- and tere-phthaloyl chlorides. It is required in the manufacture of methylphosphonic dichloride, a key precursor for the nerve gas Sarin. HUMAN STUDIES: Potential symptoms of overexposure are irritation of eyes, skin, mucous membranes, as well as eye and skin burns. Symptoms of exposure range from mild irritation to death and include dyspnea, burns, pulmonary edema, and inflammation. Cases of thionyl chloride-induced lung injury have been noted. ANIMAL STUDIES: A 20-min exposure to 17.5 ppm proved fatal to cats. Male rats were exposed to 99% pure thionyl chloride in a whole-body inhalation chamber. Two of five males died at 1239 ppm, three of five died at 1509 ppm, and four of five died at 1989 ppm. All deaths occurred within 48 hours of exposure. Severe lung irritation and edema were reported as the cause of death.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
暴露途径
该物质可以通过吸入和摄入被身体吸收。
The substance can be absorbed into the body by inhalation and by ingestion.
来源:ILO-WHO International Chemical Safety Cards (ICSCs)
毒理性
暴露途径
吸入，吞食，皮肤和/或眼睛接触
inhalation, ingestion, skin and/or eye contact
来源:The National Institute for Occupational Safety and Health (NIOSH)
Thionyl chloride is rapidly hydrolyzed to sulfur dioxide and hydrogen chloride and the metabolism and disposition follow those two compounds. Following inhalation, sulfur dioxide is distributed throughout the body after dissolving into surface fluid. Some remains in the respiratory system for a week or more following exposure. Urinary excretion clears it from the body. Hydrogen chloride dissolves in the nasal passages. Hydrogen chloride is not metabolized; however, hydrogen and chloride ions resulting from adsorption in the respiratory tract may be distributed throughout the body.
[EN] 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS<br/>[FR] DERIVES D'AZABICYCLO [3.1.0] HEXANE 3,6-DISUBSTITUES UTILISES COMME ANTAGONISTES DU RECEPTEUR MUSCARINIQUE
申请人：RANBAXY LAB LTD
公开号：WO2004052857A1
公开（公告）日：2004-06-24
The invention relates to derivatives of 3,6-disubstituted azabicyclo [3.1.0] hexanes of structure (I). The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.
3-aryl--3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same
申请人：Seong Churlmin
公开号：US20060084676A1
公开（公告）日：2006-04-20
The present invention relates to compounds of 3-aryl-3-methyl-quinoline-2,4-diones acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of 3-aryl-3-methyl-quinoline-2,4-diones according to the present invention may be valuably used for treatment of a 5HT6 receptor relating disorders because of its excellent binding affinity for the 5HT6 receptor and excellent selectivity for the 5HT6 receptor over other receptors.
Esters of ureido-phenyl (or pyridyl) phosphinic acids
申请人：Zoecon Corporation
公开号：US04433149A1
公开（公告）日：1984-02-21
Substituted tetrahydrobenzodiazaphosphorindiones or tetrahydropyridodiazaphosphorindiones, intermediates therefore, synthesis thereof, said compounds being useful herbicides.
取代的四氢苯并二氮磷氧杂环酮或四氢吡啶二氮磷氧杂环酮，其中间体，合成方法，所述化合物可用作除草剂。
Tetrahydrobenzodiazaphosphorindiones and
申请人：Zoecon Corporation
公开号：US04520197A1
公开（公告）日：1985-05-28
Substituted tetrahydrobenzodiazaphosphorindiones or tetrahydropyridodiazaphosphorindiones, intermediates therefore, synthesis thereof, said compounds being useful herbicides.
取代的四氢苯并二氮磷酰吗啉酮或四氢吡啶二氮磷酰吗啉酮，其中间体，合成物，所述化合物为有用的除草剂。
[EN] BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE<br/>[FR] DERIVES D'AMIDE HETEROARYLE BENZOCONDENSE DE THIENOPYRIDINES UTILISEES EN TANT QU'AGENTS THERAPEUTIQUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET PROCEDES D'UTILISATION ASSOCIES
申请人：PFIZER
公开号：WO2003106462A1
公开（公告）日：2003-12-24
The invention relates to compounds represented by the formula I and to prodrugs
or metabolites thereof, or pharmaceutically acceptable salts or solvates of
said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11
and R14, R15, R16, and R17 are as defined
herein. The invention also relates to pharmaceutical compositions containing
the compounds of formula I and to methods of treating hyperproliferative disorders
in a mammal by administering the compounds of formula I.
